Sarcopenia and Inflammation Linked to Worse Survival in mRCC
Patients who had sarcopenia and an elevated neutrophil-to-lymphocyte ratio had the worst overall survival.
Patients who had sarcopenia and an elevated neutrophil-to-lymphocyte ratio had the worst overall survival.
Patients who had high baseline troponin T levels had a more than 3-fold greater risk of MACE.
Researchers assessed pain and HRQOL measures with olaparib vs physician’s choice of treatment in patients with prostate cancer.
The 5-year metastasis-free survival was similar with trimodal therapy and radical cystectomy.
Patients receiving immunotherapy had a more durable immune response to vaccination, compared with patients receiving chemotherapy or targeted therapy.
Bone loss was observed in both treatment arms, but abiraterone plus prednisone did not increase bone loss.
By blinded independent review, there was a 39% reduction in the risk of progression or death with olaparib.
Men of African ancestry had the highest risk of developing metastatic prostate cancer when compared with men of other ancestries.
The objective response rate was 40%.
Enzalutamide was associated with net benefits in deterioration-free survival at 3 years, despite having some negative effects on health-related quality of life.